POJK 35 Bab XVI 2020

DVLA MERK
Comparative Balance Sheets 31 des 2022
Current Assets 1,447,973,511,000 795,587,313,000
Non Current Assets 561,165,974,000 242,059,927,000
Total Assets 2,009,139,485,000 1,037,647,240,000
Current Liabilities 482,343,743,000 239,074,429,000
Long-Term Debt 123,175,161,000 41,331,162,000
Stockholders Equity 1,403,620,581,000 757,241,649,000
Total Liability and Equity 2,009,139,485,000 1,037,647,240,000

Book Value of Invested Capital 1,526,795,742,000 798,572,811,000

(equity + interest bearing Debt)

Comparative Income Statements 31 Des 2022 16 27

Sales 1,917,041,442,000 1,124,599,738,000
Cost of Sales 910,918,060,000 697,007,762,000
Gross Margin 1,006,123,382,000 427,591,976,000
General and administrative 776,654,228,000 177,771,836,000
EBITDA 229,469,154,000 249,820,140,000
56,100,000,000 Depreciation 28,224,788,000 8,645,998,000
EBIT 201,244,366,000 241,174,142,000
Interest Expense 171,149,000 3,395,773,000
Net income before taxes 201,073,217,000 237,778,369,000
Taxes 51,698,206,000 57,940,610,000
Net income 149,375,011,000 179,837,759,000

Market Value per share/ kapan ? 31 Des 2022 2,370 4,750

Shares Outstanding 1,120,000,000 448,000,000
Market Capitalization 2,654,400,000,000 2,128,000,000,000
add : Market Value of debt 123,175,161,000 41,331,162,000
Market Value of Invested Capital 2,777,575,161,000 2,169,331,162,000

Capital Structure (market)

DVLA MERK
Valuation Multiples
Price/book value 1.89 2.81
Price/sales 1.38 1.89
price/earnings 17.77 11.83
price/gross cashflow (NI+Dep) 14.95 11.29
MVIC/BVIC 1.82 2.72
MVIC/sales 1.45 1.93
MVIC/EBIT 13.80 8.99
MVIC/EBITDA 12.10 8.68
 PEHA PYFA (Subject Company) - Persh TBK

948,943,887,000 540,992,487,000
857,337,078,000 979,576,167,000
1,806,280,965,000 1,520,568,654,000
710,243,131,000 297,388,369,000
324,221,760,000 780,822,123,000 64%
771,816,074,000 442,358,161,000 36%
1,806,280,965,000 1,520,568,653,000 1,223,180,284,000

1,096,037,834,000 1,223,180,284,000

4 0.92 kali
1,168,474,434,000 715,425,027,000
605,599,409,000 464,580,401,000
562,875,025,000 250,844,626,000
445,225,293,000 67,788,148,739
117,649,732,000 183,056,477,261
15,952,638,000 7,062,227,000
101,697,094,000 175,994,250,261
60,194,977,000 87,085,850,739
41,502,117,000 263,080,101,000
14,106,863,000 - 12,391,910,000
27,395,254,000 275,472,011,000

685 1,897 865

840,000,000 535,080,000 535,080,000
575,400,000,000 1,014,862,216,080 462,844,200,000
324,221,760,000 780,822,123,000 780,822,123,000
899,621,760,000 1,795,684,339,080 1,243,666,323,000

PEHA Weighted Average Average Industry Subject Company

0.75 0.00 -
0.49 0.00 -
21.00 0.00 -
13.27 0.00 -
0.82 1.79 2,183,997,846,379 -
0.77 1.38 989,141,489,635 -
8.85 10.55 1,856,326,798,244 928,163,399,122
7.65 9.48 1,735,041,879,916 867,520,939,958

MVIC Subject 1,795,684,339,080

Long-Term Debt (780,822,123,000)
Indikasi Nilai Ekuitas Minoritas 1,014,862,216,080
Diskon Marketabilitas -
Nilai Saham Minoritas 1,014,862,216,080
Lembar Saham 535,080,000
Nilai per lembar saham 1,897
 1.77

Nilai intrinsik saham

adalah 1897,
sedangkan harga
pasar saham adalah
865. Sehingga saham
tersebut undervalued
dan keputusannya
adalah membeli
saham.

Bobot
 0%
0%
50%
50%
100%

0% 30% s/d 50% POJK 35 pasal 41

lembar
PT Darya-Varia Laboratoria Tbk | Balance Sheet
IDX:DVLA (MI KEY: 4811902; SPCIQ KEY: 881129)

Source: Recommended
Period Category: Custom
Period Type: Custom
Reporting Basis: Custom
Sort Order: Custom
Currency: Indonesian Rupiah (IDR)
Magnitude: Thousands (K)

Recommended: S&P Capital IQ - Standard 2022 FY 2023 FQ3 LTM

Current/Restated Current/Restated
Period Ended 12/31/2022 9/30/2023
Financial Filing Date 3/31/2023 10/27/2023
Spot Exchange Rate 1.000000 1.000000
Average Exchange Rate 1.000000 1.000000
Reported Currency Code IDR IDR

Assets (Rp.000)
Cash and Equivalents 357,020,515 340,970,110
Cash & Short Term Investments 357,020,515 340,970,110
Accounts Receivable 556,433,743 512,938,764
Other Receivables 7,991,236 18,142,015
Total Receivables 564,424,979 531,080,779
Inventory 507,999,577 532,738,347
Prepaid Exp. 3,356,108 6,686,045
Other Current Assets 15,172,332 22,243,820
Total Current Assets 1,447,973,511 1,433,719,101
Gross Property, Plant & Equipment 851,929,378 901,782,365
Accumulated Depreciation (451,490,832) (487,040,327)
Net Property, Plant & Equipment 400,438,546 414,742,038
Long-term Investments NA NA
Goodwill 10,279,461 10,279,461
Other Intangibles 48,478,551 44,805,492
Accounts Receivable Long-Term NA NA
Deferred Tax Assets, LT 49,959,035 53,464,824
Other Long-Term Assets 52,010,381 50,716,056
Total Assets 2,009,139,485 2,007,726,972
Liabilities (Rp.000)
Accounts Payable 107,613,348 131,937,114
Accrued Exp. 310,545,916 247,644,627
Short-term Borrowings NA NA
Current Portion of Leases 413,517 426,146
Curr. Income Taxes Payable 3,202,661 4,570,598
Other Current Liabilities 60,568,301 59,148,832
Total Current Liabilities 482,343,743 443,727,317
Long-Term Leases 1,474,206 1,152,999
Pension & Other Post-Retire. Benefits 121,700,955 149,559,128
Total Liabilities 605,518,904 594,439,444
Equity (Rp.000)
Common Stock 280,000,000 280,000,000
Additional Paid In Capital 78,273,607 78,273,607
Retained Earnings 1,119,272,189 1,131,731,190
Treasury Stock NA NA
Comprehensive Inc. and Other (73,925,215) (76,717,269)
Total Common Equity 1,403,620,581 1,413,287,528
Total Equity 1,403,620,581 1,413,287,528
Total Liabilities And Equity 2,009,139,485 2,007,726,972
Supplemental Items (Rp.)
ECS Total Shares Outstanding on Filing Date (actual) 1,120,000,000 1,120,000,000
ECS Total Common Shares Outstanding (actual) 1,120,000,000 1,120,000,000
Book Value per Share 1,253.23 1,261.86
Tangible Book Value 1,344,862,569 1,358,202,575
Tangible Book Value per Share 1,200.77 1,212.68
Total Debt 1,887,723 1,579,145
Net Debt (355,132,792) (339,390,965)
Debt Equiv. of Unfunded Proj. Benefit Obligation 166,274,610 NA
Debt Equivalent Oper. Leases 127,298,888 NA
Raw Materials Inventory 327,328,206 339,791,071
Work in Progress Inventory 25,755,351 36,884,252
Finished Goods Inventory 182,816,717 187,530,868
Land 18,525,491 18,525,491
Buildings 367,853,147 376,036,935
Machinery 447,720,877 461,605,922
Construction in Progress 14,258,424 42,042,578
Full Time Employees (actual) 1,256 1,271
Accumulated Allowance for Doubtful Accounts 17,083,962 17,231,712
CIQ Restatement Type Code O O
CIQ Calculation Type Code REP REP
Fair Value Measurements (Rp.000)
Level 3 Assets - Unobservable Prices NA NA
Fair Value of Assets NA NA
PT Darya-Varia Laboratoria Tbk | Income Statement
IDX:DVLA (MI KEY: 4811902; SPCIQ KEY: 881129)

Source: Recommended
Period Category: Custom
Period Type: Custom
Reporting Basis: Custom
Sort Order: Custom
Currency: Indonesian Rupiah (IDR)
Magnitude: Thousands (K)

Recommended: S&P Capital IQ - Standard 2022 FY 2023 FQ3 LTM

Current/Restated Current/Restated
Period Ended 12/31/2022 9/30/2023
Financial Filing Date 3/31/2023 10/27/2023
Spot Exchange Rate 1.000000 1.000000
Average Exchange Rate 1.000000 1.000000

(Rp.000)
Revenue 1,917,041,442 1,739,188,898
Total Revenue 1,917,041,442 1,739,188,898
Cost Of Goods Sold 910,918,060 858,646,319
Gross Profit 1,006,123,382 880,542,579

Selling General & Admin Exp. 830,427,194 800,934,078

Other Operating Expense (14,269,362) (38,923,200)
Other Operating Exp., Total 816,157,832 762,010,878
Operating Income 189,965,550 118,531,701

Interest Expense (171,149) (49,549)

Interest and Invest. Income 3,621,237 2,237,308
Net Interest Exp. 3,450,088 2,187,759
Currency Exchange Gains 6,427,134 (1,583,916)
EBT Excl Unusual Items 199,842,772 119,135,544
Gain (Loss) On Sale Of Assets 1,230,445 2,324,482
EBT Incl. Unusual Items 201,073,217 121,460,026

Income Tax Expense 51,698,206 37,559,150

Earnings from Cont. Ops. 149,375,011 83,900,876
Net Income to Company 149,375,011 83,900,876
Net Income 149,375,011 83,900,876
NI to Common Incl Extra Items 149,375,011 83,900,876
NI to Common Excl. Extra Items 149,375,011 83,900,876
Per Share Items (Rp.)
Basic EPS 133.37 74.91
Basic EPS Excl. Extra Items 133.37 74.91
Weighted Avg. Basic Shares Out. (actual) 1,120,000,000 1,120,000,000
Diluted EPS Incl. Extra Items 133.37 74.91
Diluted EPS Excl. Extra Items 133.37 74.91
Weighted Avg. Diluted Shares Out. (actual) 1,120,000,000 1,120,000,000
Normalized Basic EPS 111.52 66.48
Normalized Diluted EPS 111.52 66.48
Dividends per Share 119.00 121.00
Payout Ratio (%) 86.98 158.85
Supplemental Items (Rp.000)
EBITDA 248,677,205 179,936,146
EBITA 189,965,550 118,531,701
EBIT 189,965,550 118,531,701
EBITDAR 264,589,566 NA
Effective Tax Rate (%) 25.71 30.92
Current Domestic Taxes 54,887,975 39,867,194
Total Current Taxes 54,887,975 39,867,194
Deferred Domestic Taxes (3,189,769) (2,308,044)
Total Deferred Taxes (3,189,769) (2,308,044)
Normalized Net Income 124,901,733 74,459,715
Interest on Long-Term Debt 60,059 NA
Non-Cash Pension Expense 6,152,950 NA
Supplemental Operating Expense Items (Rp.000)
Selling and Marketing Expense 620,026,998 573,255,365
General and Administrative Expense 194,487,835 209,412,584
Net Rental Expense, Total 15,912,361 NA
Imputed Oper. Lease Interest Exp. 1,752,015 NA
Imputed Oper. Lease Depreciation 14,160,346 NA
Maintenance & Repair Expenses NA NA
CIQ Restatement Type Code O O
CIQ Calculation Type Code REP LTM
PT Darya-Varia Laboratoria Tbk | Stock Chart

IDX:DVLA (MI Key: 4811902; SPCIQ Key: 881129)

Entities: PT Darya-Varia Laboratoria Tbk, S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Ind Group) Index
Metrics: Share Price, Volume
SERIES NAME CATEGORY HIGH
DVLA-Share Price (Daily) Market Data 2,440.00
DVLA-Volume (Daily) Market Data 37,500.00
S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechno
Market Data 597.14

Pricing Date DVLA-Share Price (Daily)(Rp.) DVLA-Volume (Daily)

12/30/2022 2,370.00 3,000
12/29/2022 2,370.00 6,500
12/28/2022 2,370.00 3,800
12/27/2022 2,380.00 2,300
12/26/2022 2,400.00 800
12/23/2022 2,380.00 37,500
12/22/2022 2,370.00 400
12/21/2022 2,380.00 4,300
12/20/2022 2,380.00 1,100
12/19/2022 2,390.00 7,200
12/16/2022 2,390.00 4,700
12/15/2022 2,410.00 2,400
12/14/2022 2,400.00 1,900
12/13/2022 2,390.00 8,500
12/12/2022 2,400.00 1,500
12/9/2022 2,400.00 13,200
12/8/2022 2,390.00 25,400
12/7/2022 2,400.00 5,500
12/6/2022 2,390.00 6,600
12/5/2022 2,420.00 12,800
12/2/2022 2,440.00 9,800
12/1/2022 2,440.00 28,700
Sciences (Ind Group) Index
LOW AVERAGE CHANGE
2,370.00 2,393.64 -50.00 | -2.07%
400.00 8,540.91 -25,700.00 | -89.55%
569.10 585.89 11.14 | 1.90%

S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Ind Group) Index-Index Value (Daily)
596.10
597.14
587.59
582.61
582.94
583.30
582.38
576.70
569.10
573.20
586.80
583.71
595.15
590.61
593.14
593.53
592.82
579.96
580.47
593.18
585.25
583.85
PT Merck Tbk | Balance Sheet
IDX:MERK (MI KEY: 4811982; SPCIQ KEY: 8080963)

Source: Recommended
Period Category: Custom
Period Type: Custom
Reporting Basis: Custom
Sort Order: Custom
Currency: Indonesian Rupiah (IDR)
Magnitude: Thousands (K)

Recommended: S&P Capital IQ - Standard 2022 FY 2023 FQ3 LTM

Current/Restated Current/Restated
Period Ended 12/31/2022 9/30/2023
Financial Filing Date 4/12/2023 11/2/2023
Spot Exchange Rate 1.000000 1.000000
Average Exchange Rate 1.000000 1.000000
Reported Currency Code IDR IDR

Assets (Rp.000)
Cash and Equivalents 170,428,304 169,827,125
Cash & Short Term Investments 170,428,304 169,827,125
Accounts Receivable 136,565,034 159,789,616
Other Receivables 102,286,838 11,486,556
Total Receivables 238,851,872 171,276,172
Inventory 369,095,939 339,123,819
Prepaid Exp. 309,230 8,230,112
Other Current Assets 16,901,968 1,464,175
Total Current Assets 795,587,313 689,921,403
Gross Property, Plant & Equipment 443,417,060 456,867,008
Accumulated Depreciation (224,870,029) (242,589,649)
Net Property, Plant & Equipment 218,547,031 214,277,359
Other Intangibles 888,759 1,261,210
Deferred Tax Assets, LT 18,149,227 20,639,869
Other Long-Term Assets 4,474,910 1,640,675
Total Assets 1,037,647,240 927,740,516
Liabilities (Rp.000)
Accounts Payable 90,112,211 16,948,454
Accrued Exp. 54,738,530 37,000,681
Current Portion of Leases 6,452,768 6,087,221
Curr. Income Taxes Payable 48,063,423 46,706,858
Other Current Liabilities 39,707,497 33,931,861
Total Current Liabilities 239,074,429 140,675,075
Long-Term Leases 9,730,396 9,963,014
Pension & Other Post-Retire. Benefits 30,654,636 32,684,226
Other Non-Current Liabilities 946,130 146,142
Total Liabilities 280,405,591 183,468,457
Equity (Rp.000)
Common Stock 22,400,000 22,400,000
Additional Paid In Capital 17,561,517 17,561,517
Retained Earnings 717,280,132 704,310,542
Total Common Equity 757,241,649 744,272,059
Total Equity 757,241,649 744,272,059
Total Liabilities And Equity 1,037,647,240 927,740,516
Supplemental Items (Rp.)
ECS Total Shares Outstanding on Filing Date (actual) 448,000,000 448,000,000
ECS Total Common Shares Outstanding (actual) 448,000,000 448,000,000
Book Value per Share 1,690.27 1,661.32
Tangible Book Value 756,352,890 743,010,849
Tangible Book Value per Share 1,688.29 1,658.51
Total Debt 16,183,164 16,050,235
Net Debt (154,245,140) (153,776,890)
Debt Equiv. of Unfunded Proj. Benefit Obligation 17,605,599 NA
Debt Equivalent Oper. Leases 17,474,608 NA
Raw Materials Inventory 175,836,556 144,847,806
Work in Progress Inventory 28,908,065 27,454,492
Finished Goods Inventory 169,043,927 171,916,403
Land 692,218 692,218
Buildings 152,623,435 154,163,059
Machinery 248,897,821 254,887,810
Construction in Progress 4,546,456 11,289,801
Full Time Employees (actual) 376 381
Accumulated Allowance for Doubtful Accounts 214,517 511,888
CIQ Restatement Type Code O O
CIQ Calculation Type Code REP REP
Fair Value Measurements (Rp.000)
Level 1 Assets - Quoted Prices 410,720,181 342,524,770
Fair Value of Assets 410,720,181 342,524,770
Level 1 Liabilities - Quoted Prices 201,687,532 104,077,373
Fair Value of Liabilities 201,687,532 104,077,373
PT Merck Tbk | Income Statement
IDX:MERK (MI KEY: 4811982; SPCIQ KEY: 8080963)

Source: Recommended
Period Category: Custom
Period Type: Custom
Reporting Basis: Custom
Sort Order: Custom
Currency: Indonesian Rupiah (IDR)
Magnitude: Thousands (K)

Recommended: S&P Capital IQ - Standard 2022 FY 2023 FQ3 LTM

Current/Restated Current/Restated
Period Ended 12/31/2022 9/30/2023
Financial Filing Date 4/12/2023 11/2/2023
Spot Exchange Rate 1.000000 1.000000
Average Exchange Rate 1.000000 1.000000

(Rp.000)
Revenue 1,124,599,738 1,035,913,367
Total Revenue 1,124,599,738 1,035,913,367
Cost Of Goods Sold 697,007,762 618,548,455
Gross Profit 427,591,976 417,364,912

Selling General & Admin Exp. 190,287,812 193,730,463

Other Operating Expense 287,323 14,768,919
Other Operating Exp., Total 190,575,135 208,499,382
Operating Income 237,016,841 208,865,530

Interest Expense (3,395,773) (3,971,351)

Interest and Invest. Income 2,100,053 1,662,685
Net Interest Exp. (1,295,720) (2,308,666)
Currency Exchange Gains 2,902,627 7,427,825
EBT Excl Unusual Items 238,623,748 213,984,689
Gain (Loss) On Sale Of Assets (845,379) 187,000
EBT Incl. Unusual Items 237,778,369 214,171,689

Income Tax Expense 57,940,610 53,690,397

Earnings from Cont. Ops. 179,837,759 160,481,292
Net Income to Company 179,837,759 160,481,292
Net Income 179,837,759 160,481,292
NI to Common Incl Extra Items 179,837,759 160,481,292
NI to Common Excl. Extra Items 179,837,759 160,481,292
Per Share Items (Rp.)
Basic EPS 401.42 358.22
Basic EPS Excl. Extra Items 401.42 358.22
Weighted Avg. Basic Shares Out. (actual) 448,000,000 448,000,000
Diluted EPS Incl. Extra Items 401.42 358.22
Diluted EPS Excl. Extra Items 401.42 358.22
Weighted Avg. Diluted Shares Out. (actual) 448,000,000 448,000,000
Normalized Basic EPS 332.90 298.53
Normalized Diluted EPS 332.90 298.53
Dividends per Share 320.00 320.00
Payout Ratio (%) 59.65 89.35
Supplemental Items (Rp.000)
EBITDA 260,913,122 232,489,623
EBITA 237,016,841 208,865,530
EBIT 237,016,841 208,865,530
EBITDAR 263,097,448 NA
Effective Tax Rate (%) 24.37 25.07
Total Current Taxes 54,352,669 57,093,556
Total Deferred Taxes 3,587,941 (3,403,159)
Normalized Net Income 149,139,843 133,740,431
Interest on Long-Term Debt 1,990,771 NA
Non-Cash Pension Expense (15,566,109) NA
Supplemental Operating Expense Items (Rp.000)
Marketing Expense 19,901,903 NA
Selling and Marketing Expense 121,904,394 127,485,005
General and Administrative Expense 66,199,092 64,417,772
R&D Expense 288,159 483,494
Net Rental Expense, Total 2,184,326 NA
Imputed Oper. Lease Interest Exp. 3,254,558 NA
Imputed Oper. Lease Depreciation (1,070,232) NA
CIQ Restatement Type Code O O
CIQ Calculation Type Code REP LTM
PT Merck Tbk | Stock Chart

IDX:MERK (MI Key: 4811982; SPCIQ Key: 8080963)

Entities: PT Merck Tbk, S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Ind Group) Index
Metrics: Share Price, Volume
SERIES NAME CATEGORY HIGH
MERK-Share Price (Daily) Market Data 4,860.00
MERK-Volume (Daily) Market Data 123,900.00
S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechno
Market Data 597.14

Pricing Date MERK-Share Price (Daily)(Rp.) MERK-Volume (Daily)

12/30/2022 4,750.00 85,800
12/29/2022 4,760.00 74,000
12/28/2022 4,750.00 30,500
12/27/2022 4,740.00 42,400
12/26/2022 4,820.00 500
12/23/2022 4,760.00 6,500
12/22/2022 4,750.00 10,400
12/21/2022 4,750.00 2,800
12/20/2022 4,740.00 52,900
12/19/2022 4,830.00 2,800
12/16/2022 4,700.00 34,100
12/15/2022 4,690.00 16,000
12/14/2022 4,710.00 15,800
12/13/2022 4,710.00 15,200
12/12/2022 4,690.00 42,000
12/9/2022 4,670.00 36,500
12/8/2022 4,750.00 14,000
12/7/2022 4,780.00 14,900
12/6/2022 4,790.00 92,700
12/5/2022 4,860.00 15,700
12/2/2022 4,830.00 23,200
12/1/2022 4,830.00 123,900
LOW AVERAGE CHANGE
4,670.00 4,757.27 -130.00 | -2.66%
500.00 34,209.09 -38,100.00 | -30.75%
569.10 585.89 11.14 | 1.90%

S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Ind Group) Index-Index Value (Daily)
596.10
597.14
587.59
582.61
582.94
583.30
582.38
576.70
569.10
573.20
586.80
583.71
595.15
590.61
593.14
593.53
592.82
579.96
580.47
593.18
585.25
583.85
PT Phapros, Tbk | Balance Sheet
IDX:PEHA (MI KEY: 5246301; SPCIQ KEY: 216794040)

Source: Recommended
Period Category: Custom
Period Type: Custom
Reporting Basis: Custom
Sort Order: Custom
Currency: Indonesian Rupiah (IDR)
Magnitude: Thousands (K)

Recommended: S&P Capital IQ - Standard 2022 FY 2023 FY

Current/Restated Current/Restated
Period Ended 12/31/2022 NA
Financial Filing Date 3/29/2023 NA
Spot Exchange Rate 1.000000 NA
Average Exchange Rate 1.000000 NA
Reported Currency Code IDR NA

Assets (Rp.000)
Cash and Equivalents 147,684,064 NA
Short Term Investments NA NA
Cash & Short Term Investments 147,684,064 NA
Accounts Receivable 450,583,739 NA
Other Receivables 18,926,057 NA
Total Receivables 469,509,796 NA
Inventory 284,925,647 NA
Prepaid Exp. 2,443,159 NA
Other Current Assets 44,381,221 NA
Total Current Assets 948,943,887 NA
Gross Property, Plant & Equipment 972,527,554 NA
Accumulated Depreciation (366,988,430) NA
Net Property, Plant & Equipment 605,539,124 NA
Long-term Investments 19,418,181 NA
Goodwill 134,443,900 NA
Other Intangibles 3,428,645 NA
Deferred Tax Assets, LT 14,135,694 NA
Deferred Charges, LT 909,026 NA
Other Long-Term Assets 79,462,508 NA
Total Assets 1,806,280,965 NA
Liabilities (Rp.000)
Accounts Payable 64,578,665 NA
Accrued Exp. 16,171,329 NA
Short-term Borrowings 529,323,926 NA
Curr. Port. of LT Debt 75,030,748 NA
Current Portion of Leases 9,581,919 NA
Curr. Income Taxes Payable 1,834,948 NA
Unearned Revenue, Current 2,485,145 NA
Other Current Liabilities 11,236,451 NA
Total Current Liabilities 710,243,131 NA
Long-Term Debt 217,030,305 NA
Long-Term Leases 12,512,746 NA
Pension & Other Post-Retire. Benefits 94,678,709 NA
Def. Tax Liability, Non-Curr. NA NA
Total Liabilities 1,034,464,891 NA
Equity (Rp.000)
Common Stock 84,000,000 NA
Additional Paid In Capital 17,139,103 NA
Retained Earnings 475,634,170 NA
Comprehensive Inc. and Other 174,276,712 NA
Total Common Equity 751,049,985 NA
Total Minority Interest 20,766,089 NA
Total Equity 771,816,074 NA
Total Liabilities And Equity 1,806,280,965 NA
Supplemental Items (Rp.)
ECS Total Shares Outstanding on Filing Date (actual) 840,000,000 NA
ECS Total Common Shares Outstanding (actual) 840,000,000 NA
Book Value per Share 894.11 NA
Tangible Book Value 613,177,440 NA
Tangible Book Value per Share 729.97 NA
Total Debt 843,479,644 NA
Net Debt 695,795,580 NA
Debt Equiv. of Unfunded Proj. Benefit Obligation 94,679 NA
Debt Equivalent Oper. Leases 18,681,512 NA
Total Minority Interest 20,766,089 NA
Raw Materials Inventory 132,450,227 NA
Work in Progress Inventory 10,969,766 NA
Finished Goods Inventory 145,372,553 NA
Land 302,161,300 NA
Buildings 129,946,454 NA
Machinery 463,723,313 NA
Construction in Progress 23,077,603 NA
Full Time Employees (actual) 1,513 NA
Assets under Capital Lease - Gross 1,559,907 NA
Assets under Cap. Lease, Accum. Depr. (623,962) NA
Accumulated Allowance for Doubtful Accounts 769,194 NA
CIQ Restatement Type Code O NA
CIQ Calculation Type Code REP NA
PT Phapros, Tbk | Income Statement
IDX:PEHA (MI KEY: 5246301; SPCIQ KEY: 216794040)

Source: Recommended
Period Category: Custom
Period Type: Custom
Reporting Basis: Custom
Sort Order: Custom
Currency: Indonesian Rupiah (IDR)
Magnitude: Thousands (K)

Recommended: S&P Capital IQ - Standard 2022 FY 2023 FQ3 LTM

Current/Restated Current/Restated
Period Ended 12/31/2022 9/30/2023
Financial Filing Date 3/29/2023 10/31/2023
Spot Exchange Rate 1.000000 1.000000
Average Exchange Rate 1.000000 1.000000

(Rp.000)
Revenue 1,168,474,434 1,071,955,367
Total Revenue 1,168,474,434 1,071,955,367
Cost Of Goods Sold 605,599,409 555,131,236
Gross Profit 562,875,025 516,824,131

Selling General & Admin Exp. 426,830,598 430,298,207

Depreciation & Amort. 15,375,132 14,936,400
Amort. of Goodwill and Intangibles 577,506 622,584
Other Operating Expense 2,542,662 (317,425)
Other Operating Exp., Total 445,325,898 445,539,766
Operating Income 117,549,127 71,284,365

Interest Expense (61,755,898) (65,651,701)

Interest and Invest. Income 3,430,688 3,940,342
Net Interest Exp. (58,325,210) (61,711,359)
Currency Exchange Gains 175,724 160,832
Other Non-Operating Inc. (20,921,035) (11,866,458)
EBT Excl Unusual Items 38,478,606 (2,132,620)
Gain (Loss) On Sale Of Assets 34,130 211,643
Asset Writedown 97,000 97,000
Insurance Settlements 2,892,381 3,727,737
EBT Incl. Unusual Items 41,502,117 1,903,760

Income Tax Expense 14,106,863 6,209,176

Earnings from Cont. Ops. 27,395,254 (4,305,416)
Net Income to Company 27,395,254 (4,305,416)
Minority Int. in Earnings 674,617 97,165
Net Income 28,069,871 (4,208,251)
NI to Common Incl Extra Items 28,069,871 (4,208,251)
NI to Common Excl. Extra Items 28,069,871 (4,208,251)
Per Share Items (Rp.)
Basic EPS 33.42 (5.01)
Basic EPS Excl. Extra Items 33.42 (5.01)
Weighted Avg. Basic Shares Out. (actual) 840,000,000 840,000,000
Diluted EPS Incl. Extra Items 33.42 (5.01)
Diluted EPS Excl. Extra Items 33.42 (5.01)
Weighted Avg. Diluted Shares Out. (actual) 840,000,000 840,000,000
Normalized Basic EPS 29.43 (1.47)
Normalized Diluted EPS 29.43 (1.47)
Dividends per Share 13.37 13.37
Payout Ratio (%) 35.01 NM
Supplemental Items (Rp.000)
EBITDA 158,576,106 77,461,218
EBITA 117,556,772 71,284,365
EBIT 117,549,127 71,284,365
EBITDAR 160,911,295 NA
Effective Tax Rate (%) 33.99 326.15
Total Current Taxes 13,829,176 6,595,002
Total Deferred Taxes 277,687 (385,826)
Normalized Net Income 24,723,746 (1,235,723)
Interest on Long-Term Debt 1,560,921 NA
Non-Cash Pension Expense 5,193 NA
Supplemental Operating Expense Items (Rp.000)
Selling and Marketing Expense 230,952,567 235,195,783
General and Administrative Expense 15,700,277 15,667,847
R&D Expense 29,003,699 36,425,105
Net Rental Expense, Total 2,335,189 NA
Imputed Oper. Lease Interest Exp. 1,341,220 NA
Imputed Oper. Lease Depreciation 993,969 NA
Maintenance & Repair Expenses 33,572,588 NA
CIQ Restatement Type Code O O
CIQ Calculation Type Code REP LTM
PT Phapros, Tbk | Stock Chart

IDX:PEHA (MI Key: 5246301; SPCIQ Key: 216794040)

Entities: PT Phapros Tbk, S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Ind Group) Index
Metrics: Share Price, Volume
SERIES NAME CATEGORY HIGH
PEHA-Share Price (Daily) Market Data 785.00
PEHA-Volume (Daily) Market Data 390,900.00
S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechno
Market Data 597.14

Pricing Date PEHA-Share Price (Daily)(Rp.) PEHA-Volume (Daily)

12/30/2022 685.00 226,700
12/29/2022 680.00 230,500
12/28/2022 690.00 61,000
12/27/2022 685.00 104,000
12/26/2022 695.00 25,800
12/23/2022 700.00 139,300
12/22/2022 695.00 34,500
12/21/2022 695.00 61,000
12/20/2022 695.00 13,300
12/19/2022 695.00 17,400
12/16/2022 700.00 390,900
12/15/2022 710.00 86,700
12/14/2022 715.00 286,800
12/13/2022 725.00 251,500
12/12/2022 735.00 64,200
12/9/2022 735.00 297,600
12/8/2022 755.00 58,900
12/7/2022 760.00 104,800
12/6/2022 765.00 223,800
12/5/2022 775.00 149,400
12/2/2022 785.00 89,900
12/1/2022 785.00 197,800
LOW AVERAGE CHANGE
680.00 720.91 -110.00 | -13.84%
13,300.00 141,627.27 28,900.00 | 14.61%
569.10 585.89 11.14 | 1.90%

S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Ind Group) Index-Index Value (Daily)
596.10
597.14
587.59
582.61
582.94
583.30
582.38
576.70
569.10
573.20
586.80
583.71
595.15
590.61
593.14
593.53
592.82
579.96
580.47
593.18
585.25
583.85
PT Pyridam Farma Tbk | Balance Sheet
IDX:PYFA (MI KEY: 4812181; SPCIQ KEY: 8292738)

Source: Recommended
Period Category: Custom
Period Type: Custom
Reporting Basis: Custom
Sort Order: Custom
Currency: Indonesian Rupiah (IDR)
Magnitude: Thousands (K)

Recommended: S&P Capital IQ - Standard 2022 FY 2023 FY

Current/Restated Current/Restated
Period Ended 12/31/2022 NA
Financial Filing Date 4/6/2023 NA
Spot Exchange Rate 1.000000 NA
Average Exchange Rate 1.000000 NA
Reported Currency Code IDR NA

Assets (Rp.000)
Cash and Equivalents 136,579,597 NA
Cash & Short Term Investments 136,579,597 NA
Accounts Receivable 148,947,621 NA
Other Receivables 2,807,430 NA
Total Receivables 151,755,051 NA
Inventory 210,193,784 NA
Prepaid Exp. 9,506,230 NA
Other Current Assets 32,957,825 NA
Total Current Assets 540,992,487 NA
Gross Property, Plant & Equipment 1,240,029,735 NA
Accumulated Depreciation (393,335,299) NA
Net Property, Plant & Equipment 846,694,435 NA
Long-term Investments 100,593,954 NA
Goodwill NA NA
Other Intangibles 11,170,212 NA
Deferred Tax Assets, LT 16,761,385 NA
Other Long-Term Assets 4,356,181 NA
Total Assets 1,520,568,654 NA
Liabilities (Rp.000)
Accounts Payable 68,693,526 NA
Accrued Exp. 51,712,506 NA
Short-term Borrowings 137,429,090 NA
Curr. Port. of LT Debt 16,701,993 NA
Current Portion of Leases 5,675,725 NA
Curr. Income Taxes Payable 2,345,525 NA
Other Current Liabilities 14,830,003 NA
Total Current Liabilities 297,388,369 NA
Long-Term Debt 742,023,899 NA
Long-Term Leases 8,207,320 NA
Pension & Other Post-Retire. Benefits 30,591,578 NA
Other Non-Current Liabilities (674) NA
Total Liabilities 1,078,210,492 NA
Equity (Rp.000)
Common Stock 53,508,000 NA
Additional Paid In Capital 2,065,085 NA
Retained Earnings 372,668,425 NA
Comprehensive Inc. and Other 13,885,441 NA
Total Common Equity 442,126,951 NA
Total Minority Interest 231,210 NA
Total Equity 442,358,161 NA
Total Liabilities And Equity 1,520,568,654 NA
Supplemental Items (Rp.)
ECS Total Shares Outstanding on Filing Date (actual) 535,080,000 NA
ECS Total Common Shares Outstanding (actual) 535,080,000 NA
Book Value per Share 826.28 NA
Tangible Book Value 430,956,739 NA
Tangible Book Value per Share 805.41 NA
Total Debt 910,038,028 NA
Net Debt 773,458,430 NA
Debt Equiv. of Unfunded Proj. Benefit Obligation 30,591,578 NA
Debt Equivalent Oper. Leases 42,817,380 NA
Total Minority Interest 231,210 NA
Raw Materials Inventory 20,753,318 NA
Work in Progress Inventory 9,943,249 NA
Finished Goods Inventory 189,587,180 NA
Other Inventory Accounts 4,794,649 NA
Land 257,688,231 NA
Buildings 530,586,625 NA
Machinery 420,326,119 NA
Construction in Progress 8,894,741 NA
Full Time Employees (actual) 1,175 NA
Accumulated Allowance for Doubtful Accounts 11,350,342 NA
CIQ Restatement Type Code O NA
CIQ Calculation Type Code REP NA
PT Pyridam Farma Tbk | Income Statement
IDX:PYFA (MI KEY: 4812181; SPCIQ KEY: 8292738)

Source: Recommended
Period Category: Custom
Period Type: Custom
Reporting Basis: Custom
Sort Order: Custom
Currency: Indonesian Rupiah (IDR)
Magnitude: Thousands (K)

Recommended: S&P Capital IQ - Standard 2022 FY 2023 FY

Current/Restated Current/Restated
Period Ended 12/31/2022 NA
Financial Filing Date 4/6/2023 NA
Spot Exchange Rate 1.000000 NA
Average Exchange Rate 1.000000 NA

(Rp.000)
Revenue 715,425,027 NA
Total Revenue 715,425,027 NA
Cost Of Goods Sold 464,580,401 NA
Gross Profit 250,844,626 NA

Selling General & Admin Exp. 286,433,306 NA

Other Operating Expense (31,176,241) NA
Other Operating Exp., Total 255,257,065 NA
Operating Income (4,412,439) NA

Interest Expense (86,910,857) NA

Interest and Invest. Income 4,309,203 NA
Net Interest Exp. (82,601,654) NA
Currency Exchange Gains (278,681) NA
Other Non-Operating Inc. (174,994) NA
EBT Excl Unusual Items (87,467,767) NA
Gain (Loss) On Sale Of Assets 725,724 NA
Other Unusual Items 349,822,144 NA
EBT Incl. Unusual Items 263,080,101 NA

Income Tax Expense (12,391,910) NA

Earnings from Cont. Ops. 275,472,011 NA
Net Income to Company 275,472,011 NA
Net Income 275,472,011 NA
NI to Common Incl Extra Items 275,472,011 NA
 NI to Common Excl. Extra Items 275,472,011 NA
Per Share Items (Rp.)
Basic EPS 514.82 NA
Basic EPS Excl. Extra Items 514.82 NA
Weighted Avg. Basic Shares Out. (actual) 535,080,000 NA
Diluted EPS Incl. Extra Items 514.82 NA
Diluted EPS Excl. Extra Items 514.82 NA
Weighted Avg. Diluted Shares Out. (actual) 535,080,000 NA
Normalized Basic EPS (102.17) NA
Normalized Diluted EPS (102.17) NA
Payout Ratio (%) NA NA
Supplemental Items (Rp.000)
EBITDA 60,935,116 NA
EBITA (2,982,533) NA
EBIT (4,412,439) NA
EBITDAR 66,287,288 NA
Effective Tax Rate (%) NM NA
Current Domestic Taxes 3,808,732 NA
Total Current Taxes 3,808,732 NA
Deferred Domestic Taxes (16,200,642) NA
Total Deferred Taxes (16,200,642) NA
Normalized Net Income (54,667,355) NA
Interest on Long-Term Debt 66,815,572 NA
Non-Cash Pension Expense 13,526,101 NA
Supplemental Operating Expense Items (Rp.000)
Marketing Expense 78,828,973 NA
Selling and Marketing Expense 172,665,931 NA
General and Administrative Expense 108,415,203 NA
R&D Expense 11,280,066 NA
Net Rental Expense, Total 5,352,172 NA
Imputed Oper. Lease Interest Exp. 5,477,114 NA
Imputed Oper. Lease Depreciation (124,941) NA
CIQ Restatement Type Code O NA
CIQ Calculation Type Code REP NA
PT Pyridam Farma Tbk | Stock Chart

IDX:PYFA (MI Key: 4812181; SPCIQ Key: 8292738)

Entities: PT Pyridam Farma Tbk, S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Ind Group) Index
Metrics: Share Price, Volume
SERIES NAME CATEGORY HIGH
PYFA-Share Price (Daily) Market Data 985.00
PYFA-Volume (Daily) Market Data 436,100.00
S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechno
Market Data 597.14

Pricing Date PYFA-Share Price (Daily)(Rp.) PYFA-Volume (Daily)

12/30/2022 865.00 11,400
12/29/2022 865.00 4,800
12/28/2022 860.00 30,200
12/27/2022 895.00 4,500
12/26/2022 900.00 3,900
12/23/2022 895.00 12,500
12/22/2022 885.00 44,600
12/21/2022 890.00 271,700
12/20/2022 940.00 26,100
12/19/2022 915.00 23,100
12/16/2022 940.00 6,800
12/15/2022 950.00 1,100
12/14/2022 955.00 35,400
12/13/2022 940.00 3,300
12/12/2022 970.00 5,200
12/9/2022 940.00 32,100
12/8/2022 950.00 12,100
12/7/2022 970.00 3,500
12/6/2022 970.00 30,000
12/5/2022 965.00 66,200
12/2/2022 985.00 423,500
12/1/2022 965.00 436,100
(Ind Group) Index
LOW AVERAGE CHANGE
860.00 927.73 -75.00 | -7.98%
1,100.00 67,640.91 -424,700.00 | -97.39%
569.10 585.89 11.14 | 1.90%

S&P Asia Pacific Emerging BMI Pharmaceuticals, Biotechnology & Life Sciences (Ind Group) Index-Index Value (Daily)
596.10
597.14
587.59
582.61
582.94
583.30
582.38
576.70
569.10
573.20
586.80
583.71
595.15
590.61
593.14
593.53
592.82
579.96
580.47
593.18
585.25
583.85